Objective Steroid pulse therapy is used to relieve pancytopenias in our hospital and is effective in some patients. However, it is unclear which patients will benefit from such therapy. Thus, we retrospectively analyzed the clinical features of patients undergoing allogeneic hematopoietic stem cell transplantation who received steroid pulse therapy to facilitate recovery in their blood cell counts. Methods Between 2004 and 2012, 24 patients underwent steroid pulse therapy and the medical records of 17 of these evaluable patients (11 men, 6 women) were retrospectively reviewed. Bone marrow smears were assessed to calculate the proportion of hemophagocytic macrophages just prior to receiving pulse therapy. Results Steroid pulse therapy was started at a median of 15 days after transplantation (range, 10-28 days). The median white blood cell count was 0.02×10 3 /μL (range, 0.01-0.4×10 3 /μL). Eight patients responded to pulse therapy and subsequent engraftment was achieved in all responders. None of the patients who underwent cord blood transplantation responded to the pulse therapy. Among the non-responders, only two patients achieved engraftment and four of nine non-responders died within one month. When evaluating the efficacy of steroid pulse therapy according to the ferritin level and proportion of hemophagocytic macrophages among patients undergoing bone marrow or peripheral blood stem cell transplantation, both values were higher in responders than in non-responders. Conclusion We speculate that responders have a hemophagocytic syndrome which is responsive to steroid pulse therapy. Thus, our results imply that the use of ferritin levels in combination with the proportion of hemophagocytic macrophages may be useful for the early detection of potential hemophagocytic syndrome after hematopoietic stem cell transplantation.
Introduction
Despite marked progress in therapeutic strategies for patients undergoing allogeneic stem cell transplantation (allo-SCT), prolonged cytopenia remains problematic. Steroid pulse therapy is used to relieve pancytopenias in our hospital, in particular when a hemophagocytic syndrome (HPS) is suspected, and appears to be effective in some patients. However, this judgment is quite subjective and it is unclear which patients will benefit from such therapy. Therefore, we retrospectively analyzed the clinical features of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) who received steroid pulse therapy to facilitate recovery in their blood cell counts.
Materials and Methods
Between June 2004 and August 2012, a total of 515 patients received allo-SCT in our hospital. Of these, 24 paHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan and Laboratory Medicine Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan tients received steroid pulse therapy to facilitate recovery in their blood cell counts. Six patients were excluded from our analysis due to the lack of data (i.e., a ferritin or bone marrow examination before pulse therapy). One patient who died during the pulse therapy was also excluded. Thus, we retrospectively reviewed the medical records of the remaining 17 patients. Bone marrow smears were assessed to calculate the proportion of hemophagocytic macrophages just prior to receiving pulse therapy. A hemophagocytic macrophage was defined as a macrophage including hematocyte(s) in its cytoplasm, and macrophages containing only granules were excluded. The proportion of hemophagocytic macrophages was calculated as a percentage of hemophagocytic macrophages among all macrophages. A bone marrow smear review was performed by several professional technicians in the division of laboratory medicine in our hospital who were blinded to the patient data and clinical course.
Steroid pulse therapy comprising 500 mg/day or 1,000 mg/day of methylprednisolone (mPSL) for 3 days was administered. The dose of mPSL was determined at the physician's discretion. Steroid pulse therapy was considered effective when: 1) the white blood cell (WBC) count exceeded 100/μL within 3 days after the end of pulse therapy if the pre-pulse WBCs were below 100/μL; or 2) the WBCs increased 2-fold within 3 days after the end of pulse therapy if the pre-pulse WBCs were 100-500/μL. Engraftment was defined as the first day of three consecutive days with neutrophil counts above 500/μL. Most patients with lymphoid malignancy were conditioned with a myeloablative regimen comprising total body irradiation (TBI, 12 Gy) plus cyclophosphamide (CY, 120 mg/kg) ± cytarabine (8 g/m 2 ). Most patients with myeloid malignancy were conditioned with a regimen comprising intravenous busulfan (BU, 12.8 mg/kg) and CY (120 mg/kg). Most patients undergoing the reduced intensity conditioning (RIC) regimen received either fludarabine (125 mg/m 2 ), melphalan (120 mg/m 2 ) and low-dose (4 Gy) TBI or fludarabine (180 mg/m 2 ), BU (6.4 mg/kg intravenously), and low-dose TBI.
The overall survival (OS) was calculated from the first day of steroid pulse therapy to final follow-up or death. The outcome was estimated using Kaplan-Meier methods and compared using the log-rank test. Statistical analysis was performed using the PSPP II software package (SPSS, Chicago, USA). Statistical analyses were two-sided, and p<0.05 was considered to be statistically significant.
Results
The patient characteristics are summarized in Table 1 . The population consisted of 11 men and 6 women with a median age of 60 years (range, 20-71 years). Eight patients were conditioned with a myeloablative regimen, and nine patients were conditioned with a non-myeloablative regimen. With respect to the donor source, eight patients underwent unrelated bone marrow transplantation (BMT), three patients underwent related peripheral blood stem cell transplantation (PBSCT), and six patients underwent unrelated cord blood transplantation (CBT). Granulocyte colony-stimulating factor was administered from five days after allo-SCT (day 5) in all patients. The pulse therapy was started at a median of day 15 (range, 10-28) after allo-SCT (median: day 14.5 in responders vs. day 16 in non-responders, p=0.226). The median WBC count was 0.02×10 3 /μL (range, 0.01-0.4×10 3 /μL). Fifteen patients received pulse therapy at a dose of 1,000 mg/ day, and two patients received pulse therapy at a dose of 500 mg/day. No patients received ongoing steroid therapy after the pulse therapy (Table 2) .
Eight patients responded to the pulse therapy, and subsequent engraftment was achieved at a median of 18.5 days after allo-SCT in all responders. None of the patients who underwent CBT responded to the pulse therapy. Among the non-responders, only two patients, one of whom underwent a second course of HSCT, achieved engraftment and four of nine non-responders died within one month. The OS was significantly shorter in non-responders (50% OS: 353 days in responders vs. 47 days in non-responders, p=0.0012. Fig. 1 ). When evaluating the efficacy of the pulse therapy according to the ferritin level and the proportion of hemophagocytic macrophages among patients who underwent BMT or PBSCT, both values were high (ferritin >1,500 ng/ mL; proportion of hemophagocytic macrophages >25%) in all responders (Fig. 2) .
Discussion
In this study, the efficacy of steroid pulse therapy for blood cell count recovery was retrospectively analyzed. Among patients undergoing BMT or PBSCT, all responders showed higher ferritin levels and a higher proportion of hemophagocytic macrophages compared with non-responders. Conversely, no CBT patients responded to pulse therapy.
HPS is occasionally observed after HSCT, and several studies have reported that HPS-HSCT followed by engraftment failure in the context of either allogeneic or autologous HSCT resulted in a poor survival (1) (2) (3) (4) . An increased number of hemophagocytic cells in the bone marrow obtained around day 14 is associated with a delayed or absent blood cell recovery (5) . In this report, a fever, elevated C-reactive protein level, and infectious episodes were more frequently observed in patients with increased hemophagocytic cells. A diagnosis of HPS in the pre-engraftment phase using conventional diagnostic criteria (6, 7) is very difficult, as patients already show persistent cytopenia and often have a high fever. Takagi et al. proposed a new diagnostic strategy for HPS-HSCT consisting of two major criteria (engraftment failure or delayed blood cell count recovery and hemophagocytosis) and four minor criteria (a high fever, hepatosplenomegaly, elevated ferritin level, and elevated lactate dehydrogenase (LDH) level) (4) . On the other hand, in a report by Koh et al., HPS-HSCT was diagnosed using biopsyproven hemophagocytosis and hyperferritinemia (>10,000 ng/mL) (8) . Among the patients undergoing BMT or PBSCT in our study, only one patient (case number 6) fulfilled these respective criteria. Although we cannot completely exclude the possibility that the blood cells in responders recovered spontaneously, we speculate that responders showing high ferritin levels and a high proportion of hemophagocytic macrophages have an HPS that is responsive to steroid pulse therapy in BMT or PBSCT. Indeed, blood cell count recovery was observed soon after pulse therapy in all responders. In contrast, none of the patients who underwent CBT responded to pulse therapy, even though some patients showed high ferritin levels and a high proportion of hemophagocytic macrophages. The reasons for that were unclear. However, steroid pulse therapy in CBT may inhibit blood cell count recovery by viral reactivation, such as human herpes virus 6, which has been reported to be observed more often in CBT and be associated with delayed engraftment (9) .
In summary, steroid pulse responders showed a high ferritin level and a high proportion of hemophagocytic macrophages in BMT or PBSCT. Our results suggest that the use of ferritin levels in combination with the proportion of hemophagocytic macrophages may be useful for the early detection of potential HPS-HSCT. Further investigations with larger studies are necessary to confirm these conclusions.
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